IN THE SPOTLIGHT

Long-term survival after ALK-TKI resistance through immunotherapy combined with chemotherapy in ALK-positive non-small cell lung cancer: a case report

Long-term survival after ALK-TKI resistance through immunotherapy combined with chemotherapy in ALK-positive non-small cell lung cancer: a case report

Systematic review and meta analysis of efficacy and safety of immunotherapy plus chemotherapy versus chemotherapy in non small cell lung cancer without EGFR or ALK alterations

Systematic review and meta analysis of efficacy and safety of immunotherapy plus chemotherapy versus chemotherapy in non small cell lung cancer without EGFR or ALK alterations

Resistance Mechanisms and Molecular Testing in ALK Inhibitor–Treated NSCLC

Resistance Mechanisms and Molecular Testing in ALK Inhibitor–Treated NSCLC

Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)

Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)

Triana Biomedicines Secures $120M Series B to Propel ALK-Targeted Cancer Therapy to Clinical Trials

Triana Biomedicines Secures $120M Series B to Propel ALK-Targeted Cancer Therapy to Clinical Trials

Second-Line ALK TKI Therapy Plus Chemotherapy Bests Chemo Alone in ALK+ NSCLC

Second-Line ALK TKI Therapy Plus Chemotherapy Bests Chemo Alone in ALK+ NSCLC

Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis

Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.